Drug
Oritavancin clinical trials
Also written Orbactiv and Kimyrsa.
- studies test it
- 10
- open now
- 1
- in phase 3
- 0
- first study started
- 2007
Keep track of what changes. Save the oritavancin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Studies by the year they started
10 studies that test it; most in 2015 (3)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2014 | 1 |
| 2015 | 3 |
| 2017 | 1 |
| 2019 | 2 |
| 2023 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 3
- Phase 4
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 2
Melinta Therapeutics, Inc. (3) · Melinta Therapeutics, LLC (2) · The Medicines Company (2) · Targanta Therapeutics Corporation (1) · Kirby Institute (1) · University of Pennsylvania (1)
Studies
Open first, then newest update. How each study uses oritavancin is read from its arms, and is right about nine times in ten.
Testing it · 10
- Oritavancin for Treatment of Serious Cardiac InfectionsNot yet recruitingPhase 2Kirby InstituteNCT07550595Written as Oritavancin
- Open Label, Dose-finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Participants With Suspected or Confirmed Bacterial InfectionsCompletedPhase 1Melinta Therapeutics, LLCNCT02134301Written as Oritavancin
- Study to Evaluate the Safety of Intravenous Oritavancin for the Treatment of Children With Skin InfectionsCompletedPhase 2Melinta Therapeutics, LLCNCT05599295Written as Orbactiv
- Safety of Either a Single or Two Intravenous Doses of Orbactiv in Participants With Acute Bacterial Skin and Skin Structure InfectionCompletedPhase 4The Medicines CompanyNCT02925416Written as Oritavancin
- Oritavancin on the Results of Multiple Coagulation Tests in Healthy VolunteersCompletedPhase 1Melinta Therapeutics, Inc.NCT02357524Written as Oritavancin
- Multiple Oritavancin Doses on Safety, Tolerability, and Pharmacokinetics in Healthy SubjectsCompletedPhase 1Melinta Therapeutics, Inc.NCT02470702Written as Oritavancin
- Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a New Formulation of Oritavancin in Healthy VolunteersCompletedPhase 1The Medicines CompanyNCT02471690Written as Oritavancin
- Oritavancin for Staphylococcus Aureus Infections in Opioid UsersWithdrawnPhase 4University of PennsylvaniaNCT03761953Written as Oritavancin Injection
- Relative Exposure and Safety Study of Kimyrsa in ABSSSI PatientsCompletedPhase 1Melinta Therapeutics, Inc.NCT03873987Written as Current Formulation of Oritavancin
- A Study for Patients With Complicated Skin and Skin Structure InfectionsCompletedPhase 2Targanta Therapeutics CorporationNCT00514527Written as oritavancin
Given in every arm · 1 — oritavancin is usual care beside what is tested
As the comparator · 1 — what is tested is compared with oritavancin
Codes
What other systems call oritavancin · ClinicalTrials.gg INT003925
- MeSH (NLM) C100708oritavancinConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) PUG62FRZ2EORITAVANCINConfirmed FDA, NLM, Wikidata
- RxNorm 1547611Confirmed FDA, Wikidata
- Wikidata Q7102878oritavancinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C174855OritavancinOne source FDA
- DrugBank DB04911One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C100708 | oritavancin | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | PUG62FRZ2E | ORITAVANCIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1547611 | — | Confirmed FDA, Wikidata |
| Wikidata | Q7102878 | oritavancin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C174855 | Oritavancin | One source FDA |
| DrugBank | DB04911 | — | One source Wikidata |
Also registered as oritavancin diphosphate (UNII VL1P93MKZN · RxNorm 1549827).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.